文献速递心律失常

血管细胞黏附分子1与心房颤动的关联

Association Between Vascular Cell Adhesion Molecule 1 and Atrial Fibrillation.
PubMed 文献 · JAMA Cardiol · 2017-01-01

Bruneck前瞻性人群队列研究(n=909)随访20年,在基线无房颤的880人中117人发生房颤(发病率8.2/1000人年,95%CI 6.8-9.6)。可溶性VCAM-1每升高1个标准差,多变量模型HR为1.34(95%CI 1.11-1.62),呈剂量反应关系,并在SAPHIR病例对照研究(n=1770)中成功重复验证。

要点

  • 可溶性VCAM-1与20年新发房颤独立相关,每升高1个标准差多变量HR为1.34。
  • 骨保护素初始与房颤相关,但年龄性别校正后失去显著性(HR 1.05)。
  • 其余11种炎症标志物经Bonferroni校正后均未达统计学显著。

核心结论

  • 在一般社区人群中,可溶性VCAM-1水平(而非其他炎症标志物)与新发房颤显著相关。
  • 未来研究应探讨可溶性VCAM-1能否在标准风险评分信息之外改善房颤风险分类。

研究设计与样本

  • Bruneck研究为前瞻性、基于人群的队列研究,随访20年,样本量n=909,为40至79岁一般社区随机样本,1990年基线测量13种炎症标志物水平。
  • 结果在SAPHIR前瞻性研究嵌套的病例对照样本中重复验证,样本量n=1770。
  • 数据分析于2016年2月至5月进行。

主要发现

  • Bruneck研究909名参与者平均(标准差)年龄为58.8(11.4)岁,女性448人(49.3%)。
  • 基线无房颤的880名参与者中,20年随访期间117人发生房颤,发病率为8.2/1000人年(95%CI 6.8-9.6)。
  • 可溶性VCAM-1和骨保护素水平与房颤发生显著相关,HR分别为1.49(95%CI 1.26-1.78)和1.46(95%CI 1.25-1.69),经Bonferroni校正P均<.001;但骨保护素在年龄和性别校正后失去显著性(HR 1.05;95%CI 0.87-1.27;Bonferroni校正P>.99)。
  • 基质金属蛋白酶9、金属蛋白酶抑制剂1、单核细胞趋化蛋白1、P-选择素、纤维蛋白原、核因子κB受体活化因子配体、高敏C反应蛋白、脂联素、瘦素、可溶性细胞间黏附分子1和E-选择素在Bonferroni校正后(未校正及年龄性别校正分析)均未达统计学显著。
  • 多变量模型中,可溶性VCAM-1每升高1个标准差,HR为1.34(95%CI 1.11-1.62;Bonferroni校正P=.03),呈剂量反应关系,至少与N末端B型利钠肽原的关联强度相当(后者每升高1个标准差多变量HR为1.15;95%CI 1.04-1.26),在各亚组中内部一致。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Accumulating evidence links inflammation and atrial fibrillation (AF). OBJECTIVE: To assess whether markers of systemic and atrial inflammation are associated with incident AF in the general population. DESIGN, SETTING, AND PARTICIPANTS: The Bruneck Study is a prospective, population-based cohort study with a 20-year follow-up (n = 909). The population included a random sample of the general community aged 40 to 79 years. Levels of 13 inflammation markers were measured at baseline in 1990. Findings were replicated in a case-control sample nested within the prospective Salzburg Atherosclerosis Prevention Program in Subjects at High Individual Risk (SAPHIR) study (n = 1770). Data analysis was performed from February to May 2016. EXPOSURES: Levels of 13 inflammation markers. MAIN OUTCOMES AND MEASURES: Incident AF over a 20-year follow-up period in the Bruneck Study. RESULTS: Of the 909 participants included in the Bruneck Study, mean [SD] age was 58.8 (11.4) years and 448 (49.3%) were women. Among the 880 participants free of prevalent AF (n = 29) at baseline, 117 developed AF during the 20-year follow-up period (incidence rate, 8.2; 95% CI, 6.8-9.6 per 1000 person-years). The levels of soluble vascular cell adhesion molecule 1 (VCAM-1) and osteoprotegerin were significantly associated with incident AF (hazard ratio [HR], 1.49; 95% CI, 1.26-1.78; and 1.46; 95% CI, 1.25-1.69, respectively; P < .001 with Bonferroni correction for both), but osteoprotegerin lost significance after age and sex adjustment (HR, 1.05; 95% CI, 0.87-1.27; P > .99 with Bonferroni correction). Matrix metalloproteinase 9, metalloproteinase inhibitor 1, monocyte chemoattractant protein-1, P-selectin, fibrinogen, receptor activator of nuclear factor-κB ligand, high-sensitivity C-reactive protein, adiponectin, leptin, soluble intercellular adhesion molecule 1, and E-selectin all fell short of significance (after Bonferroni correction in unadjusted and age- and sex-adjusted analyses). The HR for a 1-SD higher soluble VCAM-1 level was 1.34 (95% CI, 1.11-1.62; Bonferroni-corrected P = .03) in a multivariable model. The association was of a dose-response type, at least as strong as that obtained for N-terminal pro-B-type natriuretic peptide (multivariable HR for a 1-SD higher N-terminal pro-B-type natriuretic peptide level, 1.15; 95% CI, 1.04-1.26), internally consistent in various subgroups, and successfully replicated in the SAPHIR Study (age- and sex-adjusted, and multivariable odds ratios for a 1-SD higher soluble VCAM-1 level, 1.91; 95% CI, 1.24-2.96, P = .003; and 2.59; 95% CI, 1.45-4.60; P = .001). CONCLUSIONS AND RELEVANCE: Levels of soluble VCAM-1, but not other inflammation markers, are significantly associated with new-onset AF in the general community. Future studies should address whether soluble VCAM-1 is capable of improving AF risk classification beyond the information provided by standard risk scores.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Willeit K, Pechlaner R, Willeit P, et al. Association Between Vascular Cell Adhesion Molecule 1 and Atrial Fibrillation. JAMA Cardiol. 2017. PMID: 28355442. doi:10.1001/jamacardio.2017.0064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。